An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia.
Aged
Antibodies
/ blood
Anticoagulants
/ adverse effects
Biomarkers
/ blood
Canada
Female
Germany
Heparin
/ adverse effects
Humans
Immunoglobulin G
/ blood
Immunologic Tests
/ standards
Laboratory Proficiency Testing
Male
Middle Aged
Observer Variation
Pilot Projects
Platelet Factor 4
/ immunology
Predictive Value of Tests
Reproducibility of Results
Singapore
Thrombocytopenia
/ blood
blood platelets
heparin
laboratory proficiency testing
platelet factor 4
thrombocytopenia
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
26
09
2018
pubmed:
15
1
2019
medline:
9
4
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Essentials A pilot study for External Quality Assessment for testing of HIT is described. The qualitative accordance for the PF4/heparin IgG test was 97.6%. The qualitative accordance for functional HIT tests was considerably lower. External Quality Assessment for functional HIT tests is required. SUMMARY: Objective Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin exposure. Diagnosis is most reliable using a combination of an enzyme immunoassay (EIA) that detects antibodies against platelet factor 4 (PF4)/heparin complexes ("antigen" assay) and a "functional" assay that detects platelet-activating properties of the pathogenic HIT antibodies. No External Quality Assessment (EQA) is available for a combination of the tests. Here we report on the results of the first international EQA. Methods The pilot EQA was organized by the Department of Transfusion Medicine, Universitätsmedizin Greifswald, Germany. Six serum samples of patients, which were referred to Greifswald for HIT diagnosis, and one negative control sample were distributed to seven participants in Germany, Canada, and Singapore. Participants were asked to report the optical density (OD) values of their local EIA test for IgG-specific antibodies against the PF4/heparin complexes and the results for a functional assay (HIPA or SRA). Consensus was defined as a minimum 70% agreement, i.e., agreement among at least five of the seven participating laboratories. Results and conclusion Six out of seven participants reported results for EIA, with a high quantitative accordance (97.6%). For the functional assay, consensus was reached for all samples except the negative control, for which some participants reported nonspecific reactivity. All HIT-negative samples were correctly diagnosed by all participants; for HIT-positive samples, consensus of 70% was reached. Although the limited availability of sample material is an obstacle to overcome, an EQA combining both EIA and functional testing is feasible.
Identifiants
pubmed: 30640980
doi: 10.1111/jth.14383
pii: S1538-7836(22)02832-X
doi:
Substances chimiques
Antibodies
0
Anticoagulants
0
Biomarkers
0
Immunoglobulin G
0
PF4 protein, human
0
Platelet Factor 4
37270-94-3
Heparin
9005-49-6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-531Informations de copyright
© 2019 International Society on Thrombosis and Haemostasis.